Solara Active Pharma Sciences Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6wkx92idyqs49087v1y4z3uf.pdf

Key Takeaways


The FY24 Reset: Sacrificing Revenue for Discipline

Arun Kumar: "I'm very confident that Solara will hit its historical highs of its EBITDA in the next 6 to 8 quarters, and we will meet our guidance, which we are reaffirming again today in spite of the 1quarter delay that we had originally expected."

COVID Inventory Provisioning

Arun Kumar: "We took a prudent decision to take a provisioning of this inventory such that the focus for this financial year and going forward would purely be based on an operating leverage the company is focused on."

Vizag Plant: Retrofit and FDA Outcome


Balance Sheet & Rights Issue


New Products and the Growth Path


Guidance & Commitments

CommitmentSpecificsTimeline
FY25 revenueApproximately INR1,500 croresFY25
FY25 EBITDA run rateINR260 crores to INR290 croresFY25
FY25 EBITDA exit run rateAlmost INR80 croresQ4 FY25 exit
Gross margin recoveryAchieve historical levels of ~50%-51%During FY25
EBITDA return to historical highsHit historical highs of EBITDANext 6 to 8 quarters
Vizag retrofit completionAll activities completed, ~1,000 KL capacity availableFY25
Non-COVID excess inventory liquidationOver INR100 crores used, improving cash flowWithin FY25
Insurance claim (Puducherry)First ad-hoc amount of INR10 crores received~1 month
Long-term revenue CAGR15% to 18% top-line CAGRAfter FY25

Key Metrics

MetricQ4 FY24
Revenue₹1,300 cr (FY24 full year); FY25 guidance of approx. ₹1,500 cr
Gross marginMoved almost 10 percentage points QoQ, approaching historical highs of 50%-51%
Reported EBITDA₹11 cr
Adjusted EBITDANearly ₹38 cr
EBITDA guidance (FY25)₹260 cr to ₹290 cr run rate, with exit run rate of almost ₹80 cr
COVID inventory provisionApprox. ₹120-odd cr provisioned in Q4
Revenue growth target (FY25)15%-16% (implied from ₹1,300 cr to ₹1,500 cr)
Long-term revenue CAGR target (post FY25)15% to 18%
Regulated market sales share75% of sales
New product contribution (FY25)Approx. ₹150 cr to ₹200 cr of ₹1,500 cr guidance
Ibuprofen contribution to salesAbout ₹500-₹600 cr
Cost reduction program (full year)₹60 cr to ₹75 cr base cost reduction from previous year
Quarterly cost run rate reduction₹15 cr per quarter
US DMFs filedClose to 95
US DMFs commercializedRoughly 25 to 30
Insurance claim (Puducherry incident)Around ₹50 cr claimed; first adhoc amount of ₹10 cr expected
Potential revenue on current asset baseClose to about ₹2,500 cr without new large capex